This inventor holds 1 USPTO granted patent. Top assignee: Genmab Holding B.v.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Andreas Hollenstein
Introduction
Andreas Hollenstein is a notable inventor recognized for his contributions to the field of biotechnology. He has made significant strides in the development of monoclonal antibodies, particularly in relation to anti-CD37 antibodies. His work has implications for therapeutic applications in various medical conditions.
Latest Patents
Hollenstein holds a patent titled "Methods of Use of Anti-CD37 Antibodies, Monoclonal Anti-CD37 Antibodies." This patent highlights his innovative approach to utilizing these antibodies in medical treatments. He has 1 patent to his name, showcasing his commitment to advancing scientific knowledge and therapeutic options.
Career Highlights
Andreas Hollenstein is currently employed at Genmab Holding B.V., a leading biotechnology company focused on developing differentiated antibody therapeutics for the treatment of cancer. His role at Genmab allows him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Hollenstein has worked alongside talented colleagues such as Simone Oostindie and Frank Beurskens. Their combined expertise fosters an environment of innovation and progress within their projects.
Conclusion
Andreas Hollenstein's work in the field of monoclonal antibodies exemplifies the impact of innovative thinking in biotechnology. His contributions continue to pave the way for advancements in medical treatments.